In collaboration with

Along with advanced medicines, precision medicine is the next big thing.  Globally there is a big demand, and in the UK, it has been highlighted as an area of focus for the Industrial Strategy with an extra £210m of funding announced as part of the 2017 white paper.   Precision medicine aims to treat patients based upon their individual characteristics including genomics, environmental and lifestyle data.  It has the potential to have major impacts on patient outcomes and reduce the costs associated with ineffective treatments.  However, there are still challenges with this approach, including increasing complexity and volume of data available and reimbursement issues.

This event will look at drivers for precision medicine from discovery through to development of new therapies and how building collaborative relationship could be key for overcoming the barriers and driving innovation.

Programme:

09:15 Registration

09:45 Welcome

10:00 Keynote: Professor Sir Mark Caulfield, Professor of Clinical Pharmacology at Barts and the London School of Medicine and Dentistry
The UK Precision Medicine Platform and Successes

• The UK Genomic and multi omic landscape
• The unique link to the NHS
• The opportunities for industry
• New technologies, analytics and next steps

10:30 Keynote: Dr Athena Matakidou, Head of Clinical Genomics at the Centre for Genomics Research, AstraZeneca
Transforming drug research and development through genomics

• The value of genomics in drug discovery and development
• AstraZeneca's Genomic Initiative
• Future opportunities 

11:00 Professor David van Heel, Professor of Genetics, Blizard Institute, Queen Mary University of London
Genes & Health: knockouts, monogenic and polygenic risk in British South Asians

11:30 Professor Claude Chelala, Professor of Bioinformatics, Barts Cancer Institute, Queen Mary University of London
Data integration for patient benefit
 

12:00 Networking Lunch

13:15 Driving innovations in precision based treatments

Presentations include:

13:15 Dr Steve Gardner, Co-founder and CEO, Precisionlife
Multi-factorial Patient Stratification: Case Studies in Breast Cancer and Asthma

13:40 Dr Erik Alcantar, Translational Science Director, Celyad
NKG2D-based Chimeric Antigen receptor-T Cells for Cancer Treatment

14:05 Dr Renaud Burrer, CSO, Cerba Research
Immunohistochemistry in Precision Medicine

14:30 Dr David Harland, Medical Head of Personalised Healthcare, Roche
How can we address actionability in the genomics age?

15:00 Break and networking

15:30 Panel – How can we collaborate to enable precision medicine?

Moderated  by:

Dr Steve Gardner

Panellists include:

Dr Jelena Polajeva, Business Development Manager, NIHR Office for Clinical Research Infrastructure

Professor Rakesh Uppal, Director Barts Life Sciences, Professor of Cardiovascular Surgery, Barts Heart Centre

Jane Theaker, CEO, Kinomica Ltd

Dr David Harland, Medical Head of Personalised Healthcare, Roche

16:30 Closing Remarks

16:35 Drinks and networking

18:00 Close

Prices

Gold Members and Academics: £75 + VAT

Silver Members: £175 + VAT

Non-Members: £275 + VAT

Interested in exhibiting?  If you would like to find out more then please contact alicia@onenucleus.com

*This button will not work if you are not logged in*